Across TCGA pan-cancer cohorts, RPL35AP30 RNA is linked to patient survival in 12 of 34 cancer types, making it the most broadly survival-associated RPL35AP30 data layer.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher RPL35AP30 RNA is associated with better overall survival. In most high-consensus cancer types, elevated RPL35AP30 expression acts as an unfavorable survival marker, although some lineages such as BLCA and HNSC show a favorable association.
BLCA, READ, and LUSC are the cancer types where RPL35AP30 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.